£70 million investment in biotech spin-out Trogenix to tackle aggressive cancers

A new chapter has opened in the fight against hard-to-treat cancers after the Edinburgh University spin-out Trogenix secured a £70 million Series A financing round. The company, built on research from the University of Edinburgh, aims to push its lead programmes into first-in-human trials for aggressive solid tumours, starting with brain cancer.

Trogenix’s platform, known as Odysseus, combines two mechanisms: selective cancer cell killing and immune-system activation while sparing healthy tissue. It employs what are called Synthetic Super Enhancers, or SSEs, which identify diseased cell states rather than relying solely on individual gene targets. These SSEs deliver a cytotoxic pro-drug converting enzyme and an immune-stimulating cytokine to target and destroy tumour cells.

The lead programme focuses on glioblastoma multiforme, one of the most aggressive and treatment-resistant brain cancers. First patient dosing is anticipated in the first quarter of 2026. Follow-on programmes include colorectal cancer liver metastases, hepatocellular carcinoma and non-small-cell lung cancer.

The funding round was led by IQ Capital, with participation from founding investor 4BIO Capital. Returning investors included Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund. New investors such as Eli Lilly and Company, Meltwind, LongeVC and Calculus Capital also joined the round.

The scale of the investment is regarded as a major validation of Trogenix’s technological promise and the strength of Scotland’s life-sciences ecosystem. According to Dr Andrea Taylor of Edinburgh Innovations, the raise demonstrates the “strength of Scottish innovation in life sciences and advanced therapeutics.”

For the biotech investor community and for patients, Trogenix represents a significant case of academia-to-industry transition. The company’s approach is ambitious, aiming to deliver potentially curative therapies for tumours with very high unmet need. The planned move into the clinic within a relatively short time frame adds to the momentum.

The involvement of major pharmaceutical companies such as Eli Lilly highlights growing industry interest in early-stage synthetic biology and immune-oncology platforms. For the UK and Europe, the investment underscores the value of university spin-outs and the innovation ecosystem that supports them.

Moving from pre-clinical success to clinical proof remains challenging. Even with £70 million in hand, Trogenix faces regulatory hurdles, manufacturing scale-up issues and the ever-present risk of safety or efficacy setbacks in first-in-human trials. Observers will be watching closely to see whether the SSE approach delivers on its promise of specificity and minimal off-target effects.

Nevertheless, for Trogenix and its investors, the potential reward is transformative. Success could lead to a new class of therapeutics for cancers that currently carry very poor prognoses. For the UK biotech sector, this milestone funding round brings renewed confidence, ambition and international visibility.

© Copyright BioCareers UK 2025. All rights reserved.